In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Swedish Oprhan Biovitrum to sell Cometriq in the EU for Exelixis; rights transition to new partner

Executive Summary

Exelixis Inc. (oncology) has chosen Swedish Orphan Biovitrum AB (Sobi; rare disease drugs) to exclusively sell Cometriq (cabozantinib) in the European Union for metastatic medullary thyroid cancer (MTC). The term of the deal is three years.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register